Kintor Pharmaceutical Ltd (HK:9939) has released an update.
Kintor Pharmaceutical Ltd reports a significant reduction in net loss by 66.3% for the first half of 2024, attributed to decreased research and development costs, particularly in dermatology, and lower administrative expenses. The company highlights its strong cash position, which supports ongoing clinical trials and R&D, though no interim dividend will be paid. Kintor also notes progress in its clinical trials, with six drug candidates at various stages of development.
For further insights into HK:9939 stock, check out TipRanks’ Stock Analysis page.